Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

HPV 16/18 Linked to Increased Relapse Risk in Cervical Cancer

December 19th 2017

Persistent HPV 16/18 infection correlated with higher locoregional relapse, overall relapse, and was also associated with early relapses in women with locally advanced cervical cancers treated with radical radiochemotherapy.

Dr. Mahantshetty Discusses Chemoradiation in Cervical Cancer

December 16th 2017

Umesh Mahantshetty, MD, MBBS, radiation oncologist, Tata Memorial Hospital, Mumbai, discusses chemoradiation in patients with cervical cancer.

Study Finds Significant Survival Disparities in HPV-related Cancer

December 9th 2017

Younger patients, women, and white patients with HPV-related cancers had superior survival at 5 years, indicating that increased HPV vaccination and better access to cancer screening and treatment are likely needed to reduce survival disparities

Dr. Haldorsen Discusses the Challenges With Imaging in Endometrial Cancer

November 28th 2017

Ingfrid Haldorsen, MD, University of Bergen, Haukeland University Hospital, discusses the challenges with imaging in endometrial cancer.

Promise on the Horizon in Advanced Endometrial Cancer

November 21st 2017

Alexandra Taylor, MD, discusses the advances with targeted therapies in endometrial cancer, as well as the challenges that still exist in the treatment and management of patients with advanced disease.

Involved Margins, High-Risk HPV Post-Treatment Predict Treatment Failure in Cervical Cancer

November 14th 2017

Results from a systemic review and meta-analysis of data collected from nearly 45,000 women treated for cervical precancer found that high-risk HPV posttreatment was a more accurate predictor of treatment failure than incomplete rescission.

Soft Tissue Sarcoma: An Increasing Number of Options

November 14th 2017

Second-Line Therapy Options: Role of Trabectedin

November 14th 2017

Soft Tissue Sarcoma: Decisions Following Progression

November 14th 2017

Changing Treatment Landscape in Soft Tissue Sarcoma

November 14th 2017

Olaratumab's Role in Soft Tissue Sarcoma

November 14th 2017

Soft Tissue Sarcoma: Selecting Among Frontline Options

November 14th 2017

First-line Options in Soft Tissue Sarcoma

November 14th 2017

Initial Treatment Approach in Soft Tissue Sarcoma

November 14th 2017

Common Pitfalls With Treating Soft Tissue Sarcoma

November 14th 2017

Collaboration of Experts in Soft Tissue Sarcoma

November 14th 2017

Ongoing Management Decisions in Soft Tissue Sarcoma

November 14th 2017

Multidisciplinary Team in Soft Tissue Sarcoma

November 14th 2017

How Sarcoma Experts Work With Community Oncologists

November 14th 2017

Histopathological Diagnosis in Soft Tissue Sarcoma

November 14th 2017